14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
LGND vs XOMA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) captures the overall head-to-head institutional edge over Ligand Pharmaceuticals Inc. (LGND) on higher Unified Composite conviction (55.8/100 HOLD vs. 42.6/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while LGND wins 4–2 across the 6-pillar growth and valuation breakdown. LGND trades at $301.87 (25.8x Forward P/E, 14.4% operating margin) versus XOMA at $40.17 (21.5x Forward P/E, -3.9% operating margin).
Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. LGND 42.6/100 HOLD) and 0.68β · 37% Vol risk profile, whereas LGND leads top-line expansion (-31.8% YoY revenue growth, 1.53x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LGND vs XOMA. Trailing 12-month operating profitability (LGND 14.4% vs XOMA -3.9%) and valuation multiples (LGND 25.8x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LGND vs XOMA Key Questions & Quantitative Answers
As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) captures the overall head-to-head institutional edge over Ligand Pharmaceuticals Inc. (LGND) on higher Unified Composite conviction (55.8/100 HOLD vs. 42.6/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while LGND wins 4–2 across the 6-pillar growth and valuation breakdown. LGND trades at $301.87 (25.8x Forward P/E, 14.4% operating margin) versus XOMA at $40.17 (21.5x Forward P/E, -3.9% operating margin). Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. LGND 42.6/100 HOLD) and 0.68β · 37% Vol risk profile, whereas LGND leads top-line expansion (-31.8% YoY revenue growth, 1.53x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
LGND leads the Growth & Scale pillar: LGND posts -31.8% YoY revenue growth and +825.0% YoY earnings growth on $254M TTM revenue (86.1% gross margin, 14.4% operating margin), compared with XOMA at -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin). On trailing 12-month operating scale, LGND generates $254M in USD-normalized revenue versus $49M for XOMA. In operating R&D and SG&A reinvestment, LGND deploys 71.7% of Rev ($182M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XOMA.
XOMA screens cheaper on headline valuation multiples. LGND trades at 25.8x Forward P/E, 127.0x Trailing P/E, 1.53x PEG, and 29.3x EV/Revenue (22.6% FCF margin), whereas XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LGND (5.4% ROE) versus XOMA (34.2% ROE) capital efficiency.
In options market volatility and institutional positioning, LGND carries 37.9% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.99β · 38% Vol realized risk). By comparison, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.